Pekna, Marcela
Siqin, Sumen
de Pablo, Yolanda
Stokowska, Anna
Torinsson Naluai, Åsa
Pekny, Milos
Funding for this research was provided by:
Vetenskapsrådet (2017-00991, 2021-01486, 2017-02255, 2019-00284, 2020-01148)
The Swedish state under the agreement between the Swedish government and the county councils, the ALF agreement (716591, 966011, 724421, 965939)
Hjärnfonden (FO2017-0004, FO2020-0134, FO2018-0252, FO2021-0082)
The Swedish Stroke Foundation
T. Söderberg’s Foundations
W. and M. Lundgren’s Foundation
Hagströmer’s Foundation Millennium
University of Gothenburg
Article History
Received: 7 July 2022
Revised: 7 July 2022
Accepted: 29 August 2022
First Online: 12 September 2022
Declarations
:
: A. Stokowska, M. Pekny, and M. Pekna hold United States and European patent patent “C3a receptor agonists for use against ischemic brain injury, stroke, traumatic brain injury, spinal cord injury and neurodegenerative disorders” (US 11,266,715, EP 3541402). The other authors declare no competing interests.
: The protocols were approved by the Animal Ethics Committee of the University of Gothenburg, Sweden (Permit number: 41-2015).